A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM

Exclusion Criteria

• •Type 2 Diabetes mellitus
• •Previous participation in this trial. Participation is defined as being randomised
• •Receipt of any medicinal product in clinical development within 60 days prior to this trial
• •Clinically significant abnormal haematology, biochemistry, urinalysis, or coagulation screening tests, as judged by the Investigator considering the underlying disease
• •Known or suspected hypersensitivity to the trial products or related products
• •Severe hypoglycaemic events within one month prior to screening, as judged by the investigator
• •Recent administration of glucagon (within 3 months prior to Screening)
• •Clinically relevant diabetic complications as judged by the investigator
• •Women of child bearing potential not willing to use contraceptive methods